Erwinase® (crisantaspase) is an L-asparaginase enzyme derived from the bacterium Erwinia Chrysanthemi that is indicated for the treatment of Acute Lymphoblastic Leukaemia (ALL) a type of cancer that particularly affects children.
Developed at Porton in the 1960’s, PBL remains the sole global manufacturer of Erwinase® which was first registered as a product name in the UK in 1985. Since then it has been supplied to treat patients in numerous countries around the world.
For additional information on Erwinase® including possible side effects please see the patient information leaflet (PIL).
This link will take you to electronic Medicines Compendium (eMC) website which is a non PBL website.
If you experience any potential/possible side effects as a patient, please inform your healthcare professional.
If you are a healthcare professional, please report adverse events to porton.pv@tepsivo.com.
For any other medical information query, please contact us at medinfo@portonbiopharma.com.
If you are a motivated person who is interested in working in a high-tech environment as part of a dynamic team, then there could be a role for you.
Registered in England and Wales, company number 9331560. Registered office at Manor Farm Road, Porton Down, Salisbury, Wiltshire SP4 0JG. VAT number is GB 206 6518 18.